2022-09-21| In-DepthSpecial

ESMO 2022: Promising Trials Highlights That Are Worth Following

by Elena Chen
Share To
This year's event, organized by the European Society for Medical Oncology (ESMO), took place in Paris from September 9 to 13. This congress is an oncology event for international HCPs, the majority from Europe. 

As the opening conference remarked, sustainability will be the heart of many discussions. “Sustainability is about maintaining important, high-quality processes over time. In oncology, seeing the rise in cancer cases, we need to ask ourselves how we can ensure the essential process of caring for patients can be maintained,” said ESMO President Prof. Solange Peters.

For cancers that are not currently avoidable, screening and early detection can both maximize individuals’ chances of survival and alleviate the burden on health systems by reducing the proportion of patients with advanced diseases who require costly, chronic therapies and care.  

This year has been a fructiferous year for oncologists, with many positive clinical trial results and upgrades from previous clinical trials. As many new drugs are ongoing, we’ll focus on those discussed most lately. 

It's free! Log in now to read

Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top